Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of fremanezumab for prevention of cluster headache
2016-003172-43Phase 3Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fremanezumab in Cluster Headache (CH) (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Long-term safety of fremanezumab. Started Dec 2016; status: terminated.
02
Drugs
fremanezumab
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on 2016-003172-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003172-43.